VISTA: A promising target for overcoming immune evasion in gynecologic cancers
S Liu, F Ji, Y Ding, B Ding, S Feng, C Brennick… - International …, 2024 - Elsevier
Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment but has
shown limited efficacy in gynecologic cancers. VISTA (V-domain Ig suppressor of T-cell …
shown limited efficacy in gynecologic cancers. VISTA (V-domain Ig suppressor of T-cell …
LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses
Immune checkpoint blockade is a promising approach to activate antitumor immunity and
improve the survival of patients with cancer. V-domain immunoglobulin suppressor of T cell …
improve the survival of patients with cancer. V-domain immunoglobulin suppressor of T cell …
[HTML][HTML] Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies
K Wang, Y Wang, K Yin - Journal of Cancer Research and Clinical …, 2024 - Springer
Colitis-associated colorectal cancer has been a hot topic in public health issues worldwide.
Numerous studies have demonstrated the significance of myeloid-derived suppressor cells …
Numerous studies have demonstrated the significance of myeloid-derived suppressor cells …